Although as single agents, IKK inhibitors have failed to exhibit a strong anticancer effect in ovarian cancer, they have been considered in combination with chemotherapy, particularly with cisplatin and paclitaxel, since they inhibit the cisplatin- and paclitaxel-induced NFκB activity in ovarian cancer cells [31, 61, 62]. Here, NFKB1 is linked to ovarian cancer.